

MERUS ANNOUNCES ANNUAL GENERAL MEETING RESULTS

Toronto, March 29, 2013 – Merus Labs International Inc. (“Merus”) announces the voting results from its Annual General Meeting of its shareholders held in Toronto.

A total of 11.9 million common shares representing 38.9% of Merus’ issued and outstanding common shares were represented at the meeting. All of the shareholders present in person at the meeting voted in favour of the items of business and the overall result of the votes, including the votes by proxy, were as follows:

<u>Resolution</u>	<u>For</u>	<u>Withheld</u>
Set Number of Directors at Six	8,649,601	106,140
Elect Elie Farah as a Director	10,158,361	31,991
Elect Ahmad Doroudian as a Director	10,158,141	32,211
Elect David Guebert as a Director	7,381,996	2,808,356
Elect Robert Pollock as a Director	7,573,336	2,617,016
Elect Joseph Rus as a Director	10,158,236	32,116
Elect Timothy Sorensen as a Director	7,570,336	2,620,016
Appoint Deloitte & Touche LLP as Auditors	7,007,702	6,505

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. Merus utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

For further information please contact:

Merus Labs International Inc.

Elie Farah
President and CEO
Tel: (416) 593-3701
efarah@meruslabs.com